Sensitive and specific assays for human papillomavirus (HPV) High-risk human papillomavirus (HR-HPV) is a risk factor for cervical carcinogenesis and is routinely assessed in combination with cytologic evaluation of Papanicolaou (Pap) smears. The Hybrid Capture 2 (HC2; Qiagen, Valencia, CA) tests the common 13 HR-HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68). As the main US Food and Drug Administration (FDA)-approved option for HR-HPV clinical testing since 1995, 1 its clinical sensitivity, reproducibility, and accuracy have been evaluated in a number of studies. [2] [3] [4] [5] The FDA approval, in 2009, of Cervista HPV HR (Cervista HR; Hologic, Madison, WI) offered the additional detection of a 14th HR-HPV (HPV type 66 6 ). The novel inclusion of an internal DNA control was promoted to reduce falsenegatives incurred by insufficient cellularity. The added value of HPV-66 by the Cervista HR may be minimal; HC2 reportedly cross-reacts with HPV-66, among other phylogenetically related and unrelated low-risk types. 7, 8 Given the relatively recent FDA approval of Cervista HR, there are few studies 7,9-12 that directly compare Cervista HR with the HC2 assay. Limitations in these early studies included use of a precursor to the FDA-approved assay, 7,13 low sample numbers, 13-15 indirect comparison, 10 and the use of borderline or atypical HC2 cases. 9 A recent article 16 critically analyzes the Third Wave Technologies (TWT) trial data, 6 concluding there is poor clinical specificity of the Cervista assays, which makes a direct comparison of Cervista to HC2 of significant clinical interest.
Worcester, MA) uses the HC2 assay for HR-HPV testing with "reflex" to the Cervista HPV 16/18 genotyping assay (Hologic) according to the American Society of Colposcopy and Cervical Pathology guidelines. 17 By reflecting on the recent commentary 16 and contemplating our adoption of the Cervista HR assay, we directly compared the performance of HC2 to Cervista HR with Cervista HPV 16/18 genotyping.
Materials and Methods
The institutional review board at the University of Massachusetts, Worcester, approved this study.
Patient Population
As a tertiary care hospital, UMMHC received approximately 73,673 cervical cytology cases from July 2009 through July 2010. The majority of cases are from Massachusetts, with cases also coming from Connecticut, New Hampshire, and Rhode Island. A negative diagnosis was given for 63,789 cases, with ancillary HR-HPV testing performed on 24,128 of these cases during this time interval.
Patient Specimen Selection
Consecutively received ThinPrep (Hologic) Pap specimens (n = 601) were selected for molecular testing. To obtain an unbiased estimate of the HPV prevalence in our patient population, serially accessioned cases were obtained regardless of clinician-ordered testing (ie, Pap only, HPV if atypical squamous cells of undetermined significance, HPV cotesting or genotyping) and blinded to the cytologic diagnosis. The sample number was selected to provide a number comparable to the reported cohort in the TWT trial. 6 
ThinPrep Processing and Cytologic Diagnosis
ThinPrep Pap tests were performed according to manufacturer's specifications from samples fixed in PreservCyt (Hologic) using an automated processor. The ThinPrep Imaging System (Hologic) was used for the screening of slides and automated recording of 22 microscopic fields of view for cytotechnologists to review. According to our routine clinical protocol, all cases with positive HR-HPV cotesting are referred to a cytopathologist for second review and diagnostic reporting. For the study, all NILM with a positive HPV result by any HR-HPV assay was retrospectively rescreened by a cytopathologist (E.M.K.).
HPV Assays
Specimens were tested, first using the HC2, followed by the Cervista HR and then the Cervista HPV 16/18 according to the manufacturer's instructions. 2, 6, 18 Cervista specimens yielding indeterminate ❚Table 1❚ or equivocal results (see data analysis) were retested. When sufficient specimen was available, DNA was reextracted before retesting.
HC2 Method
A hybrid (RNA probe to HPV DNA) is detected in a sandwich enzyme-linked immunosorbent assay with alkaline phosphatase-conjugated monoclonal antibodies for signal emission from a chemiluminescent substrate. 1 Results are interpreted as a ratio of relative light units to the positive control specimen. A ratio value of 1.0 relative light units/ positive control is equivalent to 5,000 viral copies. 3 
Cervista HR and Cervista HPV 16/18 Methods
Cervista uses 2 isothermal enzymatic reactions for signal amplification of the HPV and an internal DNA control probe. Each pair of oligonucleotide probes binds upstream and downstream of the target creating a 1-base-pair overlap or "flap" for enzymatic cleavage by Cleavase (Hologic). The flap forms a tertiary DNA structure with a fluorescence resonance energy transfer cassette. Cleavase releases a quantifiable fluorescent signal. The high-risk HPV assay has 3 separate oligonucleotide pools (or mixes) of HR-HPV types.
Interpretation of HPV Assays
Interpretations of HPV results were in accordance with package insert guidelines for each assay with the following exceptions: (1) HC2 ratios in the equivocal zone (between 1.0 and 2.5) were assigned a positive value for this analysis. (2) Cervista HPV 16/18 specimens with equivocal ratios between 1.60 and 2.13 (defined by laboratory validation study, 19 not the FDA-approved package insert) were retested. The final interpretation was based on the Cervista HPV 16/18 retest value, and equivocal results were considered negative according to the manufacturer's guidelines.
Biopsy Correlation
A correlation search was performed for all cervical cytology samples tested by both assays (regardless of cytology diagnosis) to find any subsequent cervical biopsy. Biopsy diagnoses were reviewed and categorized as negative, HPV changes, or cervical intraepithelial neoplasia (CIN), mild (CIN 1), moderate (CIN 2), or severe (CIN 3).
Data Analysis and Statistics
With the exception of biopsies, the data analysis was limited to cytology specimens with negative diagnoses (533/601). The age distributions in the TWT trial and our population were compared by using a 2-sided KruskalWallis analysis of variance by ranks 20 ❚Table 2❚. The HPV prevalence estimates for HC2 and Cervista HR testing were compared by using a 2-tailed McNemar test. 20 The percentages of agreement between the HC2 and Cervista HR assays were determined. A confidence interval (CI) based on HC2 as the "gold standard" was determined by using estimation of binomial parameter (PI) ❚Table 3❚ and 95% CIs constructed using the Clopper-Pearson approach. 21 Retrospective biopsy data were obtained from the 601 consecutive cases, regardless of the cytology diagnosis, for any subsequently acquired biopsy cases. Sensitivity and specificity were calculated by using surgical biopsy data as the gold standard. A positive result was defined by a diagnosis of HPV or CIN 1 through 3 due to the limited number of biopsy specimens. A receiver operating characteristic (ROC) curve was constructed with the surgical biopsy data (as the gold standard) to compare the 2 HR-HPV assays. For statistical analysis, the surgical diagnoses were split between negative and positive (HPV, CIN 1-3) owing to the limited CIN 2 and 3 surgical diagnoses. The relative accuracy of the 2 HR-HPV assays was compared by using an area under the ROC 22 The age distribution for our study is shown in Table  2 . The UMMHC overall and category age distribution is comparable to the TWT trial 6 (P = .625). A slightly higher prevalence was noted for Cervista HR (8.5% vs HC2 7.5%) ❚Table 4❚ and ❚Figure 1❚, without statistical significance (P = .458). HPV 16/18 genotyping prevalence was lower than HR-HPV and also decreased with age ( Table 4) .
The total numbers of positive HR-HPV results by each assay method were similar (Cervista HR, 45; HC2, 40; Table  3 ). Of these specimens, 28 were positive by both methods; 17 were positive by the Cervista HR and negative by the HC2; 12 were positive by the HC2 and negative by the Cervista HR; and 468 were negative for HR-HPV by both assays. The positive percentage of agreement (PPA) between the 2 HR assays was only 70%, (CI, 53.47%-83.44%), whereas the negative percentage of agreement (NPA) was higher, 95.1% (CI, 94.45%-97.95%; Table 3 ). If indeterminate cases are excluded, the NPA increases to 96.5%. Further analysis of positive Cervista HR results showed a 2 to 1 predominance of mix 1 (HPV types 51, 56, and 66) and mix 2 (HPV types 18, 39, 45, 59, and 68) over mix 3 (HPV types 16, 31, 33, 35, 52, and 58) or all mixes when the 2 HR-HPV assays were in agreement ❚Table 5❚. By contrast, the ratio was reversed when the HC2 and Cervista HR results disagreed.
In specimens that were positive or equivocal by the HPV 16/18, 19 Indeterminate categories were also examined. For the Cervista HR, these results include low genomic DNA, a high coefficient of variation (CV) percentage, and/or a low HPV FOZ ( Table 1 ). The HC2 counterpart of the indeterminate category is the "equivocal zone" (ie, ratio of 1.0-2.5) or when there is insufficient cellularity for the assay (quantity not sufficient [QNS] ). Initial indeterminate rates were 6.94% (37/533) for the Cervista HR (Table 1) indeterminate cases, there was insufficient residual specimen for Cervista HR retesting. A 0.19% rate was achieved for HC2 after inclusion of equivocal specimens into a positive category (see the "Materials and Methods" section). After retesting (by Cervista HR) or recategorization (by HC2), the Cervista HR indeterminate rate decreased from 6.94% to 1.31% (7/533; Table 1 ) and for HC2 from 1.13% to 0.19%. Of the samples tested with both assays, 37 patients had a subsequent biopsy ❚Table 7❚. The biopsy results were as follows: negative/NILM, 15; HPV changes, 8; CIN 1, 11; CIN 2, 2; and CIN 3, 1. By using biopsy data as the gold standard, we calculated HC2 sensitivity and specificity as 95.2% and 20.0%, respectively. The Cervista HR showed a sensitivity of 76.2% and specificity of 43.0%. The area under the ROC curve for the HC2 was 0.601 vs 0.631 for the Cervista; neither was statistically significant.
It is important to note that the Cervista HR results from this study were not reported for clinical management decisions ❚Table 8❚. Biopsy rates based on cytology and HC2 results ranged from 1%, when all methods had negative results (NILM, negative Cervista HR and HC2), to 21% when all methods had positive results (positive cytology and Cervista HR and HC2). HPV 16/18 genotyping of NILM HC2-positive cases may have been a determinant in the clinical decision to perform colposcopy or biopsy.
Discussion
In this study, we have shown that the Cervista HR and HC2 have similar analytic sensitivity. Our data do not support the clinical controversy suggesting that Cervista has increased analytic sensitivity and could yield increased numbers of positive HPV results (ie, lacks clinical disease specificity), leading to unnecessary overtreatment of patients. 16 To address this point, we selected NILM cases because overtreatment of this subset would have the most consequential clinical impact. In addition, this approach provides a true test of the HPV analytic sensitivity, given that cytologic bias is eliminated.
The worldwide frequency of HR-HPV ranges from 1% to 17%. [23] [24] [25] [26] In our patient population, the overall HR-HPV prevalence rates for HC2 and Cervista HR were not significantly different in any age group (7.5% vs 8.5%, respectively; P = .458; Table 4 ) and much lower than the reported TWT clinical trial 6 (8.5% for UMMHC vs 18.5% for TWT; Figure 1 ). Similar results were reported at the 26th International Papillomavirus Conference in Montreal, Canada, regarding the Shenzhen Cervical Cancer Screening Trial II. 11 The study's direct comparison of HC2 and Cervista results in women with NILM showed prevalence rates of 7.9% and 6.0%, respectively. 27 Previous studies report NILM HR-HPV positivity in women 30 years or older ranging from 4.0% to 8.2% using the HC2 assay. 26 Within this age category, our attributed to lower prevalence rates and concordant results. Several reasons may account for positive results in one assay and not the other. Borderline results were observed in 6 of the 29 discrepant cases and may be attributed to variability associated with separate DNA extractions. Use of the same DNA for both assays would be ideal; however, the HC2 would require a non-FDA-approved extraction method. In 3 of the 6 cases, all 3 mixes of the Cervista assay showed positive values (1,250-5,000 copies of HPV). However, by using only HPV FOZ threshold for data interpretation rather than the algorithmic approach, we found the result was negative (HPV FOZ <1.524). Although this approach may reduce the detection of cross-reacting, low-risk HPV, it also inhibits interpretation of coexisting HR-HPV subtypes detected in low titers. Despite this possible limitation, the Cervista HR assay, as opposed to the HC2, uses 3 mixes to identify specific HR subtypes and, therefore, has the potential to detect mixed infections. It is interesting that in the subset of 6 cases with an HPV 16/18-positive or equivocal genotype (Table 6) when the Cervista HR is positive and the HC2 is negative (n = 17), mix 1 (HPV types 51, 56, and 66) or all mixes dominate in the Cervista HR assay. In this instance with an HPV 16/18-positive specimen, one would expect mix 2 or 3 to give the highest value. Positivity in all mixes, especially with a negative HPV FOZ ratio, may be indicative of a crossreacting, low-risk HPV. In contrast, when the HR assays agree, the highest FOZ mix value correlates with the HPV 16/18 result. Together these findings raise the possibility that only specimens positive by both assays are truly positive for HR-HPV.
Given that only 28 of 57 positive specimens were positive by both methods, we tried to use biopsy diagnoses as a gold standard ( Table 7) . The HC2 showed a higher sensitivity (95.2%) for histologic detection of HPV, whereas the Cervista HR showed higher specificity (50%). At first glance, the assays seem to be different. However, this analysis has significant limitations. Colposcopy was not required for every patient, colposcopy was triggered only by HC2 results and not Cervista HR results, a low number of biopsy specimens were obtained (37 from >601 patients), and only 3 biopsies were CIN 2 or higher grade. Under these circumstances, specificity of the Cervista HR may be overestimated and sensitivity may be underestimated. In addition, the HPV/CIN 1 changes present in these biopsy specimens may be the result of lowrisk HPV and/or HR-HPV types, the former of which should not be detected by HR-HPV assays.
Each assay has some distinctive advantages. For example, the Cervista HR internal DNA control could eliminate falsenegative results. Although our data are limited, 22 (4.1%) of 533 specimens had low genomic DNA determined by the Cervista but were called negative by the HC2 (Table 1) .
HC2 prevalence was 6.2% (31/499) vs 7.5% (37/493) for the Cervista HR.
Similarly, overall prevalence of HPV genotypes 16 and 18 in the UMMHC study were lower than in the TWT trial (1.6% for UMMHC vs 5% for TWT; Table 4 ). The difference in prevalence between studies is not surprising because it is well established that prevalence varies among different populations. 23, 27 Notably, it was the high prevalence in the TWT trial that raised concerns about the analytic sensitivity of the Cervista assays.
In contrast with our study (Table 3) , the TWT trial compared a composite of HC2 and polymerase chain reaction sequencing with the Cervista HR assay with dramatically different results. Based on the TWT data, the subpopulation tested by the Cervista HR produced a prevalence rate of 20.4% vs 3.9% to 8.0% for the composite comparator (Cervista, 94/461; composite, 18/461 or 18+19/461, if indeterminate cases are deemed positive). We speculate a higher prevalence of low-risk, cross-reactive HPV subtypes unique to the TWT trial population (not reported) may have been detected by the Cervista HR but were negative or indeterminate by the composite comparator. Moreover, inclusion of polymerase chain reaction sequencing in the TWT trial (absent in our study) may contribute to the difference in prevalence. The comparative age distribution was similar between the UMMHC and TWT populations and did not account for this difference (P = .625). It is interesting that no individual Cervista probe mix was dominant (Table 5) in the discordant category of our study.
Cross-reactivity of the Cervista HR is seen with low-risk HPV types 67 and 70 (per the package insert), in addition to HPV types 6, 73, 84, and 91. 6, 7 Similarly, the HC2 is reported to cross-react with HR virus 66 and low-risk viruses (HPV types 6, 11, 26, 30, 40, 42, 53, 54, 61, 67, 70-73, 81, 83, 84, 87 , and 91 7, 8, [28] [29] [30] ). Meanwhile, additional cross-reactive HPV subtypes are likely to be identified for each assay.
Our data show that the HC2 and Cervista HR assay results overlap but are not identical. It remains unclear which assay is correct when divergent results are obtained. Our PPA between Cervista HR and HC2 was lower relative to the TWT trial (94.4% for TWT vs ~70%; Table 3 ). Although the TWT used the HC2 as the gold standard, it is arguable which assay is correct. While the HC2 and Cervista HR assays both crossreact with low-risk subtypes, the TWT trial use of a composite comparator (to eliminate low-risk, cross-reactive HPV) may explain its higher PPA. However, discordant results from TWT data represented only a small subset (19/461 [4.1%]), and redistribution of this indeterminate group (to positive or negative categories) would have limited impact on the final calculated TWT trial PPA.
The NPA in our study (95.1%; Table 3 ) was higher than in the TWT trial (84.2%). In our study, this finding can be In 18 of 22 cases, sufficient DNA was reextracted, retested with the Cervista, and produced a negative result. Based on our prevalence rate, HC2 false-negatives were predicted but, surprisingly, were not observed. These results suggest that the internal DNA control may be a minor benefit of the Cervista HR. From the technical aspect of daily assay performance, automation is preferable, and FDA-approved platforms are likely to be available for both assays in the future. The QNS rates should be lower for the Cervista HR, which requires only 2 mL, compared with the HC2, which requires 4 mL. Another consideration in a clinical laboratory setting is the need for repeated testing. We observed an indeterminate rate of 6.94% (37/533) for the Cervista HR (Table 1 ), 6.81% (35/514) for the Cervista HPV 16/18 (data not shown) vs 1.13% for the HC2 (6/533). Although the Cervista HR had a higher indeterminate rate, this rate may be due to a bias in study design because HC2 testing was performed first in the testing series.
During the editorial review of our manuscript, Belinson et al 31 reported their results comparing the Cervista HR and HC2 in a Chinese population (Shenzhen Cervical Cancer Trial II). 11 In contrast with our study, Belinson et al 31 showed a significantly higher prevalence by the HC2 assay (7.9%) compared with the Cervista HR (6.0%) in an NILM population (P < .00001). This difference may be due to the variation in the distribution of HR-HPV types in China. In support of this suggestion, an abstract 32 presented at the 27th Annual Clinical Virology Symposium and Annual Meeting of the Pan American Society for Clinical Virology showed a prevalence of 5.93% by the HC2 vs 6.93% by Cervista in an American population with negative cytology. Like our study, there was no statistical difference in HPV detection between the 2 assays.
Conclusion
Our prospective analysis of consecutive negative cytology cases directly comparing the Cervista HR and the HC2 showed an overall NPA of 95.1%, suggesting that both assays provide excellent negative predictive value for the presence of histologically relevant disease. We did not see a "2-to 4-fold" increase in women 30 years or older with negative cytology being " 'labeled' as HPV+" 16 with the Cervista HR assay. Multiple factors may contribute to the lower PPA (70%) in our study. Despite similar prevalence rates, only 49% (28/57) of the positive results were in agreement by both methods. This finding indicates that some women will receive unnecessary colposcopy or biopsy regardless of the testing method used. The present study showed that the HC2 and Cervista HR assays are similar and, by extension, should be comparable for clinical diagnostic screening of HR-HPV.
